cyrilzakka/clinical-trials huggingface dataset:
The Effect of Exercises on Pain and Kinesiophobia in Transplant Patients

Liver transplantation is a treatment method used in acute and chronic liver failure. Progressive Relaxation Exercises, which are non-pharmacological methods aimed at minimizing complications and improving the quality of life after liver transplantation, have been reported to have many benefits such as reducing acute and chronic pain, reducing fatigue and reducing muscle tension. Therefore, in this study, the effects of progressive relaxation exercises on pain and kinesiophobia in liver transplant patients were examined.

Liver transplantation is a common treatment for acute and chronic liver failure, liver malignancy and complicated cirrhosis. Although life expectancy increases after liver transplantation, some undesirable problems such as rejection, cardiovascular risk factors, hypertension, infection and malignancy occur. Preferring non-pharmacological methods to minimise complications and improve quality of life accelerates the return of the individual to normal life. Progressive Relaxation Exercises, one of these methods, can activate the parasympathetic nervous system, blood pressure, heart and respiratory rate can be kept within clinically normal limits due to vasodilatation in the blood vessels in the peripheral area and oxygen requirement is reduced. PGE has been reported to have many benefits such as reducing the effects of anxiety and stress, reducing acute and chronic pain, nausea and vomiting, facilitating sleep, reducing fatigue, reducing respiration, blood pressure, heart rate and muscle tension. Therefore, in this study, the effects of progressive relaxation exercises on pain and kinesiophobia in liver transplant patients were examined.

Eligibility Criteria:
Inclusion Criteria:

* Patients over the age of 18 who agreed to participate in the study,
* Patients undergoing Liver Transplantation
* Patients without a disabling psychiatric disorder

Exclusion Criteria:

* Patients under the age of 18 who do not agree to participate in the study.
* Those who have a psychiatric diagnosis that prevents communication.
Community Based Health Education for Prevention of Pelvic Floor Dysfunction in Fertile Women in Rural China

According to the experts in charge of the healthcare department in the Liangshan area, Liangshan is one of the largest Yi inhabited areas in China. Influenced by local culture and production history, most women there are multiparas, with more than one child, and their awareness of postpartum recovery is relatively weak. Therefore, the prevalence and incidence rate of pelvic floor dysfunction diseases is high in the Liangshan area.

In addition, women in the Liangshan area shoulder the responsibility of taking care of family members, farmland, and livestock. They play an important role in family production, which guarantees the opportunity for other family members to go out to work. However, pelvic floor dysfunction can be manifested by persistent pelvic distension, frequent urination, the urgency of urination, difficulty in urination or defecation, and pain or difficulty in sexual intercourse, which decreases the quality of normal life, and the efficiency of production, posing many psychological problems and family contradictions.

There is no research to prove the exact intervention measures that can effectively improve the pelvic floor function of women in Liangshan ethnic minority areas. This study aims to promote the formation of women's healthy living habits and behaviors, improve women's pelvic floor function, and then develop the quality of life and labor output of local women through intervention including health knowledge education and pelvic floor muscle exercise.


Eligibility Criteria:
Inclusion Criteria:

* Married women who are 18-65 years old

Exclusion Criteria:

* Women who are unable to attend the person-to-person health education classes at the first and forth month of the intervention;
* Women who have received pelvic floor muscle training, pelvic floor muscle health education, pelvic floor muscle surgery within one year of the baseline survey;
* Women who are planning pregnancy, pregnant, or have delivered a baby in the past 6 months since the baseline survey;
* Women who are unable to understand the instructions or questions from others.
LOAD VS Levofloxacine Concomitant

Comparison Efficacy of two weeks Therapy with Doxycycline,levofloxacine,Tinadizole Versus Levofloxacine,Tinadizole,Amocillin on Eradication of Helicobacter Pylori in Syrian population.


Eligibility Criteria:
Inclusion Criteria:

* Patients are aged greater than 18 years old who have H. pylori infection diagnosed by any of following three methods:
* Positive rapid urease test (CLOtest).
* Histologic evidence of H. pylori by modified Giemsa staining.
* Positive 13C-urea breath test. without prior eradication therapy and are willing to receive therapy.

Exclusion Criteria:

* Children and teenagers aged less than 18 years.
* Previous eradication treatment for H. pylori.
* Patients who took any drug, which could influence the study results such as proton pump inhibitor, H2 blocker, mucosal protective agent and antibiotics.
* History of gastrectomy.
* Gastric malignancy, including adenocarcinoma and lymphoma,
* Previous allergic reaction to antibiotics (Amoxicillin, Tinadizole,
* Doxycycline,Bismuth subsalicylate,) and prompt pump inhibitors (Es- omeprazole).
* Contraindication to treatment drugs.
* Pregnant or lactating women.
* Severe concurrent disease.
* Liver cirrhosis.
Dietary Supplement of LEHEL for the Patients With Type 2 Diabetes

Due to metabolic disorders and dietary restrictions, patients with diabetes may have different degrees of malnutrition. The primary objective of this study is to investigate whether supplementation of LEHEL, a multi-nutrients supplement, is capable to improve metabolic parameters in patients with type 2 diabetes.


Eligibility Criteria:
Inclusion Criteria:

* Subject is diagnosed with type 2 diabetes mellitus according to the Chinese type 2 diabetes prevention guide 2010, diagnostic criteria are as follows:

  (1) Diabetes symptoms（polydipsia、polyphagia, polyuria, weight loss、skin itching、blurred vision and other acute metabolic network disorder that caused by high blood sugar）combined with random blood sugar ≥11.1 OR, (2) fasting plasma glucose (FPG) ≥7.0 OR, (3) 2 h blood sugar after oral glucose tolerance test (OGTT) ≥11.1;
* Subject is between 18 and 75 years of age, inclusive.
* Subject's BMI is \>18.5 kg/m2 and \<35 kg/m2.
* If on a chronic medication such as anti-hypertensive, lipid-lowering, thyroid medication or hormone therapy, subject has been on constant dosage for at least two months prior to screening visit.

Exclusion Criteria:

* Subject that is diagnosed as type 1 diabetes, gestational diabetes and other kinds of diabetes expect type 2.
* Subject that use exogenous insulin for glucose control.
* Subject that has a history of diabetic ketoacidosis.
* Subject that has mental disorder, cancer, cirrhosis, renal disease and hepatic disease.
* Subject that has had a significant cardiovascular event less than six months prior to screening visit or has history of congestive heart failure.
* Subject that has had operation less than six months prior to screening visit.
* Subject that has taken/is currently taking any dietary supplements or medications that could profoundly affect blood glucose during the past one month prior to screening visit.
* Subject is known to be allergic or intolerant to any ingredient found in the study product.
Neuromuscular Electrical Stimulation for Intensive Care Unit-acquired Weakness Assessment

The purpose of this study is to determine whether early neuromuscular electrical stimulation is effective in the prevention of neuromuscular weakness in critical ill patients.

Randomized, controlled study of early electrical neurostimulation (vs sham) in critically ill patients.

Eligibility Criteria:
Inclusion Criteria:

* All patient
* Aged of 18 or more
* With an intended ICU stay of at least 72 hours
* Mechanically ventilated

Exclusion Criteria:

* Age less than 18 years
* Pregnant women
* Preexisting neuromuscular disease
* Patient bearing a pace maker or an implantable defibrillator.
* Poly traumatism and/or leg fracture.
* End stage disease
Robotic-Assisted da Vinci System Prophylactic Nipple-Sparing Mastectomy

This study evaluates the safety and effectiveness of the da Vinci Surgical Systems in prophylactic Nipple Sparing Mastectomy procedures.

Surgical management for breast cancer and risk-reducing techniques have evolved from radical mastectomy to other techniques such as nipple and skin sparing procedures. Nipple-sparing mastectomy (NSM) with reconstruction technology offers the opportunity to preserve the shape of both the breast and the nipple-areola complex.

This study will evaluate the safety and effectiveness of the da Vinci Surgical Systems in NSM procedures.

Eligibility Criteria:
Inclusion Criteria:

* Female between ages 18-80.
* BMI ≤ 29.
* Candidate for an NSM procedure.
* At increased risk for breast cancer and is seeking prophylactic NSM surgery or subject has breast cancer in one breast and is seeking prophylactic NSM on contralateral side.
* Breast ptosis ≤ Grade 2.
* Cup size ≤ C.
* No presence of occult cancer on the side for which she is seeking prophylactic NSM surgery as confirmed by physical exam and by preoperative imaging per institution's guidelines.

Exclusion Criteria:

* Current or prior history of ipsilateral in-situ or invasive breast carcinoma on the breast for which she is seeking prophylactic NSM surgery.
* Previous breast surgery of the ipsilateral breast (excluding needle or core biopsies and excisional biopsies performed more than 1 year prior).
* Current history of smoking or has smoked within 1 year of screening.
* Skin conditions
* Uncontrolled diabetes mellitus.
* Previous chemotherapy or radiation
* High risk for anesthesia or significant medical comorbidities
* Contraindicated for general anesthesia or surgery.
* Known bleeding or clotting disorder.
* Pregnant or suspected to be pregnant or is lactating.
Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201

An Open-label extension (OLE), expanded access study, to assess long-term safety of SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) with Methylprednisolone (4mg bid) in patients who completed study number CHL-AA-201.

An Open-label extension (OLE), expanded access study, to assess long-term safety of SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) with Methylprednisolone (4mg bid) in patients who completed study number CHL-AA-201. An exploratory endpoint of Improved safety from switching from Zytiga (aberaterone Acetate 1000mg(4 x 250 mg qd) to SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) will also be ascertained..

Eligibility Criteria:
Inclusion Criteria:

1. Written informed consent obtained prior to any study-related procedure being performed
2. Previous, uninterrupted enrollment and treatment in trial number CHL-AA-201.

Exclusion Criteria:

1. Progressive disease as ascertained by the investigator using standard-of-care evaluations.
2. CHL-AA-201 D84 blood counts of the following:

   1. Absolute neutrophil count \> 1500/µL
   2. Platelets \> 100,000/µL
   3. Hemoglobin \> 9 g/dL
3. CHL-AA-201 D84 chemistry values of the following:

   1. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 2.5 x Upper Limit of Normal (ULN)
   2. Total bilirubin \< 1.5 x ULN
   3. Creatinine\< 1.5 x ULN
   4. Albumin \> 3.0 g/dL
   5. Potassium \> 3.5 mmol/L
Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With Schizophrenia

The objective of this study is to explore the efficacy, safety and cognitive properties of Lu AE58054 as augmentation therapy to risperidone in patients with schizophrenia.

Lu AE58054 is a selective 5-HT6 antagonist that is currently being investigated for treatment of conditions of cognitive impairment associated with schizophrenia. Substantial experimental evidence suggests that selective 5-HT6 receptor antagonists may be effective in treating cognitive deficits since they have been shown to improve performance in various animal models of cognitive function and are known to enhance cholinergic and glutaminergic neuronal function.

Lu AE58054 has been investigated in healthy volunteers and patients with schizophrenia, is generally well tolerated and has a benign side-effect profile. Moreover, no safety concerns or issues have been identified to date.

The study is designed to provide data on the efficacy, safety and cognitive properties of Lu AE58054 as augmentation therapy to risperidone in patients with schizophrenia. Efficacy will be assessed in patients who are in a stable phase of their illness, but with a predefined minimum and maximum level of symptoms that will allow them to be included in the study. Patients will be randomly assigned to receive either the investigational medicinal product (IMP) or placebo as add-on therapy to their existing risperidone treatment.

Eligibility Criteria:
Inclusion Criteria:

* Primary diagnosis of schizophrenia
* Man or woman, aged between 18-65
* Patient is on an optimised dose of risperidone (within 4-8 mg/day) for the treatment of schizophrenia for a minimum of 4 weeks prior to screening
* The patient has a PANSS total score between 70 and 100 (extremes included) at screening

Exclusion Criteria:

* Primary psychiatric diagnosis other than schizophrenia
* Acute exacerbation requiring hospitalisation within the last 3 months
* Clinically significant extrapyramidal symptoms
* Clinically significant cardiovascular disease, congestive heart failure, cardiac hypertrophy, arrhythmia or bradycardia
* Significant ECG abnormalities
* In concurrent treatment with drugs inhibiting the P450 enzymes system CYP2D6 and other CYP Isozymes
* Failed to respond to adequate courses of treatment with risperidone
* Treated with an antipsychotic other than risperidone within 4 weeks prior to screening
A Single High-dose Oral Supplement of Vitamin D in Young Chinese

evaluated the effect and safety of a single high dose of cholecalciferol in Chinese young people.


Eligibility Criteria:
Inclusion Criteria:

* Healthy, younger, Chinese Hans aged from 25-35 years, including 25 and 35 years;
* haven't taken vitamin D supplement for the past 6 months;
* with a normal BMI (18-25 kg/m2);
* with baseline serum 25(OH)D \< 30 ng/ml;
* be willing to follow the instruction and complete the study.

Exclusion Criteria:

* clinically diagnosed cardiovascular disease, gastrointestinal disease, endocrine, blood, liver, lung, kidney, nerve or mental illness;
* self-reported current use of any dietary supplements containing vitamin D within the 6 months before enrollment;
* Severe anemia (hemoglobin concentration \< 70 g/L);
* Serum 25(OH)D ≥ 30 ng/mL at enrollment;
* participating in other research studies within the 3 months before enrollment;
* history of drug dependence or drug abuse;
* History of heavy drinking (drinking 14 cups or more per week, equivalent to 360 mL beer or 150 mL white wine or 45 mL liquor per cup) and smokers (more than 10 cigarette per day);
* clinical abnormal of blood biochemistry, hematology or urine laboratory values;
* current pregnancy or lactation.
Effects of Cold Application and Heparinoid on Periorbital Edema and Ecchymosis

During surgery, blood leaking from damaged blood vessels spread to the periorbital area may cause periorbital edema and ecchymosis after anterior craniotomy. This study was carried out to determine the effects of the cold application and the local heparinoid on periorbital edema and ecchymosis after craniotomy.

Periorbital edema and ecchymosis are common after anterior craniotomy. Periorbital edema and ecchymosis are not complications, they are natural outcomes of surgical trauma. However, periorbital edema prevents pupil examination and causes the patient to experience fear and anxiety with accompanying ecchymosis. Periorbital edema rate after anterior craniotomy was 36.8-100%, ecchymosis rate was 62.5%, and 30% of patients with edema did not have a pupil examination for the first 36 hours after craniotomy.The present study was carried out to determine the effects of the heparinoid creams and regular cold application performed using gel packs in controlling periorbital edema and ecchymosis after craniotomy.

Eligibility Criteria:
Inclusion Criteria: The eligible participants were those

* who were aged 18 years and older
* who had Glasgow Coma Scale score \> 15
* who had no mental and physical problems that interfere with communication
* whose vital signs were normal
* who had no ptosis
* who volunteered to participate and signed the informed consent form

Exclusion Criteria:The participants excluded from the study;

* who had Glasgow Coma Scale score \< 15
* who died during surgery
* ptosis formed after surgery
* who refused to participate
Rectal Indomethacin Versus Intraperitoneal Lidocaine for Analgesia After Laparoscopic Cholecystectomy

Hospitals, Qena, Egypt in period between May 2020 to May 2021.eighty patients was scheduled to elective laparoscopic cholecystectomy , divided Into two groups randomly using closed envelop method. Group IP lidocaine(40 patients ) received 200 ml saline containing 200 mg 2%lidocaine immediately after abdominal cO2 insufflation( pneumoperitoneum) the surgeon sprayed the total solution on the upper surface of the liver under the right subdiaphragmatic space, left subdiaphragmatic space and around the cholecystectomy site , all patients were maintained in trendelenberg position.

At the end of the laparoscopic procedure, group indomethacin (40 patients) recived two 100 mg indomethacin rectal suppositories 2 hours prior to surgery


Eligibility Criteria:
Inclusion Criteria:

* .ASA physical status 1-2 patients.
* 18-60 years old .

Exclusion Criteria:

* using or allergic to nonsteroidal anti inflammatory drugs (NSAIDs) or aspirin .
* history of serious hepatic disease.
* renal or gastrointestinal disease.
* bleeding disorder.
* body mass index BMI \<18 or ˃30 m2/kg.
* history of abdominal surgery or chronic pain disorder other than gallbladder.
* disease or allergy to lidocaine.
Can Fat Derived Stem Cells (SVF) be Used in the Treatment of Erectile Dysfunction After Prostatectomy

Prostate cancer is the most common cancer among Danish men, and the incidence is increasing. Studies have shown a high number needed to treat for each saved prostate cancer related death. Since the treatments incur many complications, there is a need to address these. After prostatectomy, 80% experience erectile dysfunction. Sexual life is a central part of people's identity, self-esteem and quality of life. Stem cells have generated a large amount of promising data suggesting that stem cells can alleviate erectile dysfunction, by regenerating nerves as well as endothelial and smooth muscle cells in the corpus cavernous.

Prostate cancer is the most common cancer among Danish men, and the incidence is increasing. Studies have shown a high number needed to treat for each saved prostate cancer related death.

After prostatectomy, 80% experience erectile dysfunction. Sexual life is a central part of people's identity, self-esteem and quality of life. Stem cells have generated a large amount of promising data suggesting that stem cells can alleviate erectile dysfunction, by regenerating nerves as well as endothelial and smooth muscle cells in the corpus cavernous.

Animal studies have used stem cell therapy to improve erectile dysfunction in rats after cavernous nerve damage, with invariable high success rate.

In this pilot study will include 30 patient's with erectile dysfunction 3-9 mdr after prostatectomy. The men have no spontaneous erectile function and no response to drug treatment.

Liposuction is carried out in general anesthesia. Isolation of stem cells will be done simultaneously and the stem cells injected into the corpus cavernous directly after the isolation is carried out.

This is a clinical study evaluating an innovative cell therapy procedure.The objective of this study was to evaluate the effects of injection of stem cell of adipose origin.

The project will run over a period of twelve months. Patients will be followed for a period of six months. Treatment efficacy will be assessed from validated questionnaires.

Eligibility Criteria:
Inclusion Criteria:

* Men who have had prostate removed due to prostate cancer regardless bilateral nerve-sparing, unilateral nerve-sparing or non-nerve-sparing surgical technique.
* Erectile dysfunction
* Sexually active/ have sexual interest
* We make no distinction for the patients are operated with

Exclusion Criteria:

* Absence of sexual interest.
* Patients with impaired health condition where anesthesia would be a risk of complications.
* BMI below 20.
* Small amount of abdominal fat assessed by. Ct abdomen.
* Patients on anticoagulant treatment.
* Men with suspicion of residual tumor.
A Single Intra-articular Injection of aMAT vs PRP in Patients With OA of the Knee

The study proposes to compare performances and safety of intra-articular injections of aMAT with those of a control group (PRP injections) for the treatment of symptomatic OA of the knee. The end-points will be determined evaluating the performances of the treatment group in terms of improvement of the symptomatology, functional recovery and radiological appearance.

The clinical trial is a prospective, randomized, controlled, two-arm, single-blind study, involving 118 patients affected by symptomatic OA of the knee joint. Eligible subjects will be randomly allocated to one of the two treatment groups, with a 1:1 randomization ratio. Respectively, 59 patients treated with a single intra-articular injection of aMAT, and 59 patients treated with a single intra-articular injection of PRP.

The patients enrolled in the study will be treated according to the study protocol and followed after treatment with periodic visits and diagnostic imaging examinations, as Magnetic Resonance Imaging at twelve and twenty-four months follow-up and X-Ray, at three, six, twelve, and twenty-four months of follow-up.

Eligibility Criteria:
Inclusion Criteria

1. Patients provided written informed consent;
2. Patients aged between 18 and 75 years;
3. Knee symptomatic OA (Kellgren-Lawrence grade 1-4)
4. Failure of conservative treatment for at least 3 months;
5. Patients agreed to actively participate in the rehabilitation protocol and follow-up program;
6. Male or female patients;
7. Women of childbearing age had to use a proven method to prevent pregnancy, before the surgical treatment.

Exclusion Criteria

1. Patients incapable to understanding and will;
2. Patients participating in previous, concurrent or not, trials (ongoing or completed within three months);
3. Patients surgically treated for the same defect within one year;
4. Patients affected by malignancy;
5. Patients affected by metabolic or thyroid disorders;
6. Patients used to alcohol or drug (medication) abuse;
7. Patients affected by synovitis;
8. Varus or valgus misalignment exceeding 15°;
9. Body Mass Index \> 40;
10. Patients with trauma within 6 months pre-operative.